Plasmodium vivax has long been a challenging parasite to study because of its unique ability to form hypnozoites—dormant forms that can reactivate weeks, months, or even years after the initial infection. Unlike the more lethal Plasmodium falciparum, P. vivax can evade complete eradication by sequestering itself in the liver, escaping the immune system and antimalarial drugs. Understanding the molecular mechanisms that maintain this hypnozoite state is essential for developing strategies to prevent relapses, which are a significant obstacle in malaria control and elimination efforts.

The authors, Vo, van Biljon, Zanghi, and colleagues, employed advanced transcriptomic and proteomic techniques to isolate and characterize the RNA-binding proteins (RBPs) that are selectively expressed during the hypnozoite phase of the parasite’s life cycle. These proteins, previously undetected in blood-stage parasites, exhibit high affinity for specific RNA motifs that are thought to regulate the translational repression necessary for maintaining dormancy in liver cells. The identification of these RBPs is a pivotal breakthrough in malaria biology, as it reveals how the hypnozoite arrests its growth and evades host defenses.

Using innovative single-cell RNA sequencing combined with crosslinking immunoprecipitation (CLIP) assays, the research team delineated the RNA interactome of each RBP. These data indicate that the proteins bind to transcripts encoding crucial cell cycle and replication factors, effectively silencing their translation and thereby halting progression into the replicative schizont stage. This insight into post-transcriptional regulation adds a new layer of complexity to the malaria parasite’s developmental control, highlighting the sophistication of its dormant state management.

Furthermore, the study demonstrated through gene knockdown experiments conducted in a humanized liver mouse model that suppression of these RNA-binding proteins leads to a premature reactivation of the hypnozoite and uncontrolled replication of liver-stage parasites. This phenomenon, while potentially catastrophic for the parasite’s survival strategy, offers a tantalizing therapeutic target. If drugs can be developed to destabilize these RBPs or alter their RNA-binding capacity, it may be possible to flush out dormant hypnozoites, making radical cure of P. vivax malaria a feasible objective.

The implications of these findings extend beyond basic parasitology into the realms of drug discovery and public health policy. Currently, the only approved drug for hypnozoite eradication, primaquine, carries significant toxicity risks and requires prolonged treatment regimens, limiting its use in vulnerable populations. Targeting the RNA-binding proteins introduced in this study could yield safer, more effective therapeutics that minimize side effects and improve patient compliance, potentially revolutionizing malaria treatment protocols worldwide.

The researchers also postulate that these RBPs might interact with host cell factors to modulate the liver microenvironment, promoting parasite survival during dormancy. This hypothesis stems from observed alterations in hepatocyte gene expression profiles subsequent to parasite invasion. Deciphering these parasite-host interactions is a promising future direction that could uncover additional biomarkers or drug targets essential for controlling P. vivax infections.

Moreover, evolutionary analysis conducted as part of the investigation shows that these RNA-binding proteins are highly conserved among P. vivax strains but are absent or significantly divergent in P. falciparum and other Plasmodium species that do not produce hypnozoites. This specificity underscores their unique adaptation to dormancy and relapse biology and may explain why P. vivax malaria remains problematic even in regions with substantial malaria control efforts.

In the broader context of infectious disease research, these findings contribute to a growing recognition of RNA-binding proteins as critical regulators of pathogen life cycles. Similar mechanisms controlling dormancy or latency have been observed in viruses and bacteria, suggesting that post-transcriptional control strategies may be a widespread evolutionary solution to balancing persistence and replication in hostile host environments.

The study’s methodological rigor is noteworthy, integrating cutting-edge molecular techniques with in vivo validation in models that closely mimic human liver biology. The team’s use of clinically relevant parasite isolates and minimally manipulated liver cultures enhances the translational potential of their results, offering a reliable platform for future drug screening and vaccine development.

Vo and colleagues emphasize that while these discoveries lay the foundation for novel therapeutic approaches, significant challenges remain. The complexity of hypnozoite biology and the fine balance it strikes between dormancy and activation require a deep mechanistic understanding before safe and effective interference is possible. Additionally, the technical difficulties in maintaining and studying hypnozoites in vitro reiterate the importance of developing robust model systems to accelerate research.

Experts in the field hail this work as a milestone in tackling P. vivax malaria. Dr. Helena Martinez, a leading malariologist not involved with the study, comments, “The identification of functionally critical RNA-binding proteins specific to hypnozoites is a paradigm shift. This research unveils a molecular Achilles’ heel in the parasite’s lifecycle that could finally enable us to eliminate the dormant reservoirs that have long thwarted eradication efforts.”

As the global health community continues to push for malaria eradication by 2030, research such as this will be instrumental in addressing the distinct challenges posed by P. vivax. The discovery of these RBPs enriches the toolkit available to scientists and healthcare providers seeking to deliver radical cures that preclude relapse, reduce transmission, and save millions of lives in endemic regions.

Overall, this study represents a vital leap forward in malaria biology, merging molecular parasitology with translational research to bring us closer to a future where P. vivax infections can be definitively controlled and ultimately eliminated. It is a testament to the power of interdisciplinary collaboration and technological innovation in solving one of the world’s oldest and deadliest diseases.

Subject of Research: Two hypnozoite-specific RNA-binding proteins in Plasmodium vivax that inhibit liver stage replication and maintain dormancy.

Article Title: Two Plasmodium vivax hypnozoite-expressed RNA-binding proteins inhibit liver stage replication.

Article References:
Vo, K.C., van Biljon, R., Zanghi, G. et al. Two Plasmodium vivax hypnozoite-expressed RNA-binding proteins inhibit liver stage replication. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73666-0

Image Credits: AI Generated

The apicoplast, an organelle found exclusively in apicomplexan parasites like Plasmodium, Toxoplasma gondii, and Babesia, represents an Achilles’ heel for these organisms. Unlike human cells, which lack this structure, the apicoplast harbors pathways vital for parasite metabolism and replication. Professor Le Roch’s team focused on two proteins within this organelle—PfRAP03 and PfRAP08—that belong to the RNA-binding domain Abundant in Apicomplexans (RAP) family. These are essential proteins that bind RNA molecules, facilitating their processing and translation into proteins critical for the parasite’s survival.

The researchers employed sophisticated genetic tools to create knockdown strains of P. falciparum, selectively silencing the genes encoding PfRAP03 and PfRAP08. The result was unequivocal: the absence of either RAP protein resulted in parasite death. This confirmed not only the proteins’ essential roles but also suggested their potential as drug targets. Remarkably, these RAP proteins were shown to interact directly with two types of RNA molecules—ribosomal RNA (rRNA) and transfer RNA (tRNA)—both indispensable for the assembly and function of the ribosomes responsible for protein synthesis within the apicoplast.

What makes these findings especially exciting is that this is the first time scientists have detailed the direct physical interaction between RAP proteins and these non-coding RNAs inside the apicoplast. “We’ve now shown mechanistically how these proteins regulate translation in an organelle that’s completely foreign to the human body,” explained Le Roch. She emphasized that humans have only six RAP proteins, whereas parasites like Plasmodium have expanded this family to over twenty. This evolutionary divergence implies that RAP proteins have parasite-specific roles, underscoring their attractiveness as targets for novel drug development.

By unraveling the precise molecular functions of PfRAP03 and PfRAP08, the study provides insight into how apicomplexan parasites control gene expression at the RNA level within the apicoplast. Ribosomal RNA and transfer RNA serve as fundamental components in the translation process, bringing amino acids to the ribosome and assembling them into functional proteins. The binding of PfRAP03 to rRNA and PfRAP08 to tRNA suggests a finely tuned regulatory mechanism that is indispensable for parasite viability. Disrupting this mechanism could halt protein synthesis, effectively killing the parasite.

The work builds on the team’s previous investigations into RAP proteins localized in parasite mitochondria, adding a new dimension by extending the analysis to the apicoplast. The detailed mechanistic understanding gained marks a significant milestone in parasitology, providing a blueprint for targeting parasite-specific molecular machinery with minimal off-target effects on human cells. This is particularly crucial in an era of increasing drug resistance, where conventional anti-malarial drugs are losing efficacy.

Importantly, the study’s implications extend beyond malaria. Other apicomplexan pathogens, such as Toxoplasma gondii, which causes toxoplasmosis, and Babesia, a parasite responsible for babesiosis—a tick-borne disease on the rise in the United States—share this specialized organelle and RAP protein family. Le Roch highlighted the potential for broad-spectrum therapies that could tackle an entire class of parasites by exploiting vulnerabilities in their unique RNA-processing systems.

The research team is now focused on determining the three-dimensional structures of these RAP protein-RNA complexes. Such structural insights will be invaluable for guiding drug design efforts, enabling the creation of molecules that can specifically disrupt the interaction between RAP proteins and their RNA partners. This strategy holds promise for the development of therapies that are highly potent against the parasites while leaving human cells unharmed, reducing side effects and improving patient outcomes.

While no drugs currently target RAP proteins, the study sets the stage for a new avenue of anti-parasitic drug discovery grounded in structural biology and molecular parasitology. By targeting essential proteins that have no counterparts in humans, the research offers a blueprint for future generations of anti-malarial drugs that could circumvent the growing problem of drug resistance and reduce the global burden of malaria and related diseases.

The study, titled “RAP proteins regulate apicoplast noncoding RNA processing in Plasmodium falciparum,” was published in the prestigious journal Cell Reports. It underscores the collaborative efforts of scientists from UC Riverside, the Stowers Institute for Medical Research, and MIT, reflecting a multidisciplinary approach that spans molecular biology, structural biology, and infectious disease research. Supported by the National Institute of Allergy and Infectious Diseases and UCR, this work exemplifies how cutting-edge science can unearth novel therapeutic targets with the potential to save millions of lives worldwide.

As efforts continue to solve the detailed structures of these RAP protein complexes, the scientific community anticipates a surge in rational drug design initiatives aimed at translating these fundamental biological insights into clinical innovations. Ultimately, this research not only advances our understanding of malaria parasite biology but also charts a hopeful course towards eradicating one of humanity’s most enduring and deadly diseases.

Subject of Research: Cells

Article Title: RAP proteins regulate apicoplast noncoding RNA processing in Plasmodium falciparum

News Publication Date: 22-Jul-2025

Web References:

• Cell Reports Article
• UCR Profile: Karine Le Roch
• UCR Center for Infectious Disease Vector Research

References: The original research article published in Cell Reports, DOI: 10.1016/j.celrep.2025.115928

Keywords: Plasmodium falciparum, apicoplast, RAP proteins, RNA-binding, ribosomal RNA, transfer RNA, malaria, parasitology, molecular biology, anti-malarial drug targets, protein synthesis, apicomplexan parasites